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1134-156 Ef fects  o f  Antidepressant Medication on Morta l i ty  in 
Patients With Congestive Heart Failure 
Grad L. Clarv. Charles Davenport, Donna Biracree, Maragatha Kuchibhatla, Dipen Shah, 
Christopher M. O'Connor, Ranga R. Krishnan, Duke University Medioa/Center, Durham, 
North Carolina. 
Major Depressive Disorder (MDD) is a common entity in patients with cardiovascular 
(CAD) disease. Studies have previously demonstrated that MDD is present in 20%-45% 
of CAD patients. Rates of depressive disorders following myocardial infarction (MI) are 
especially high, with a depressive episode in 50% of patients immediately following MI, 
and more than 70% at one year after MI. Congestive heart failure (CHF) due to ischemia 
occurs in many of these patients. Despite numerous studies in this population, few have 
focused on the prevalence of depression and its pr(xJnostic effect in patients with CHF. 
Recently Jiang st al, published results demonstrating that overall mortality in patients 
with co-morbid CHF and depression was increased at 3 months and 1 year compared to 
patients with CHF who were not depressed. MDD with CHF was found to be an indepen- 
dent risk factor for increased mortality, in the current work we have confirmed these find- 
ings, with increased mortality in patients with CHF and co-morbid depression by Beck 
Depression Inventory (BDI=10) in a group of 674 patients with ejection fraction less than 
or equal to 35%. Patients who were not depressed at baseline but had CHF had a mor- 
tality rate of 12.12%. Those patients at baseline on antidepressant medication, and in all 
likelihood responsive to medication, had a mortality rate of 14.14%, While patients who at 
baseline were depressed and treated with medication, suffered increased mortality over 
controls at 22.52%. In CHF patients with major depression whose depressive symptoms 
did not respond to medication effect had an even higher rate of mortality at 38.60% (p- 
value=0.5). This data suggests that patients with co-morbid CHF and depression and 
who remain non-responders despite medication have higher rates of mortality over those 
without depression, or those patients responsive to medication, This work proposes that 
the effect of adequately treating depression in patients with CHF may reduce mortality, 
and if the CHF/depressed patient remains non-responsive to medication, mortality may 
be significantly higher than that either depressed-responsive/CHF or non-depressed 
patients with CHF. 
1134-157 Endothelin Antagonism With Bosentan, a Dual Receptor 
Blocker, Normalizes Dyaregulatsd Transforming Growth 
Factor Bets Signaling Pathways in Rats With Chronic 
Heart Failure 
Ingeborg Schafhalter-Zoppoth, Mary O. Gray, John R. Tearlink, San Francisco VA 
Medical Center, San Francisco, California, UCSF, San Francisco, California. 
Background: We have previously shown that dysregulation of the TGF beta signaling 
pathway is correlated with adverse ventdoular remodeling in CHF. Endothelin (ET) also 
plays a central role in ventdcular remodeling and many of its actions are mediated by 
TGF beta. Therefore, we hypothesized that the beneficial effects of ET antagonism with 
bosentan on ventricular emodeling may be mediated by improvements in the TGF beta 
signaling pathway. 
Methods: Adult male Sprague-Dawley rats (270-300g) underwent coronary artery ligation 
(CAL) or sham operation (Sham group) followed by conscious echocardiography on day 
5-7 after surgery, CAL rats with ejection fraction 3 in all groups), 
Results: Baseline data (EF, body weight) showed no differences between the treatment 
groups. In myocytes from CHF rats, bosantan tended to increase inhibitory Smed6 by 
51% (p=0.13), with no effect on the positive effectors, Smad3 or Smad4. in fibroblasts 
from CHF rats, bosentan decreased Smad4 and SARA (Smad anchor for receptor acti- 
vation; p=0,018) to normal and significantly increased Smad6 (97%; p=0.026). The 
improvements in fibroblast Smad6 concentrations directly correlated with attenuation of 
ventricular dilation by bosentan, as measured by LV volume at 20 mmHg distending 
pressure (p<0.01 ; r=0.6g). 
Conclusion: These data confirm our earlier findings of TGF beta signaling pathway dys- 
regulation in CHF and demonstrate that chronic ET blockade with bosentan results in 
normalization of these pathways, Inhibition of the TGF beta pathway was directly corre- 
lated to the beneficial effects of bosentan on ventricular emodeling. These findings sug- 
gest that the TGF beta pathway may mediate the adverse effects of endothslin in CHF 
and that this pathway may be an important herapeutic target in CHF. 
1134-158 Long-Term Carved i lo l  T reatment  in Idiopathic Dilated 
Cardiomyopathy: Biological Effects Beyond 
Pharmacological Act iv i ty  
Renata De Maria. Antonello Gavazzi, Gianfranco Sinsgra, Oberdan Parodi, Carlo 
Campana, Danilo Nsglia, Mauro Ciacched, Marce)la Luvini, Luigi Lavecchia, CNR 
Clinical Physiology/nstitute, Section of Milan, Milan,/taly, Cardiovascular DpL Ospedali 
Riuniti, Bergamo, Italy. 
Background. Despite the established effects of carvedilol on morbility and mortality in 
heart failure (HF), the mechanisms of its ctinical efficacy are still poorly understood. We 
conducted a multlcenter, double-blind, randomized, placebo-controlled trial in HF 
patients with idiopathic dilated cardiomyopathy to assess the effects of carvedilol (C) on 
submaximal exercise tolerance during long-term pharmacological treatment and after 
withdrawal. Methods and Results. 99 patients with HF due to documented idiopathic 
dilated cardiomyopathy and an ejection fraction <=0.36 underwent a 2-week open-label 
challenge with C; 84 of them (mean age 54¢10 years, 64 males) were randomized to 
chronic treatment with C (n=45), titrated up to 25 mg bid (mean final dose 23.1±4.8 bid) 
or placebo (P), (n=39) on top of ACE-inhibitors and form the intention-to-treat sample. 
After 6-month treatment, Minnesota Living with Heart Failure (MLWHFQ) questionnaire, 
echo ejection fraction and submaximal exercise stress test were compared to baseline; 
exercise tolerance was again assessed after 5.4±5 days wash-out. Improvement in sub- 
maximal exercise tolerance, defined as a 20% increase and an absolute increase of at 
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least 60 sac in exercise duration after 6-month treatment vs baseline, occurred in 51% of 
C and 23% of P (p=O.01). Changes in exercise duration were 103±257 sac in C vs - 
19±160 sac in P during chronic treatment and 123±306 sac in C vs -2±178 sec in P after 
wash-out (p=0.014 for treatment effect). Peak exercise systolic blood pressure and heart 
rate did not change in both groups. MLWHFQ total score decreased by -5+12 points in C 
vs -1±9 points in P (p=O.01); MLWHFQ physical dimension score decreased by -2±5 
points in C vs 0±4 points in P (p=0.03). Ejection fraction increased by 6.1±8.9 units in C 
vs 3.2±5.2 Units in P (p=0,08). Conclusions, In idiopathic dilated cardiomyopsthy, C 
determines during long-term treatment, beyond an improvement in symptoms and sys- 
tolic function, a significant increase in submaximsl exercise tolerance, that is maintained 
even after pharmacological wash-out. The sustained effects after drug withdrawal indi- 
cate that C-inducad benefits in HF are biologically-mediated. 
1134-159 Ef fect  o f  Valeartan on Time-Adjusted and 
Hospitalization Frequency Rate in the Valsartan Heart 
Failure Trial 
Peter E. Carson, Jay N, Cohn, for the VaI-HeFT Investigators, VA Medical Center, 
Washington, Dist. of Columbia, Univereity of Minnesota, Minneapolis, Minnesota. 
Background: In the Valsartan Heart Failure Trial (VaI-HeFT), risk for time to first heart 
failure (HF) hospitalization adjudicated by the Endpoint Committee was reduced by 
27.5% with valsartan versus placebo in 5010 patients with NYHA class II-IV HF receiving 
prescribed therapy. HF and cardiovascular (CV) hospitalizations (Investigator-classified) 
were markedly reduced (HF 22.4%, CV 15,4%) by vslsartan versus placebo. Significant 
reductions were also seen in subgroups defined by background therapy (angiotensin 
converting enzyme inhibitor = ACE, beta blocker = BB), principally in patients not on BB, 
However, total hospitalization data should be adjusted for time at risk to account for dif- 
ferential mortality. 
Methods: For purposes of this analysis, cause of hospital admissions was investigator- 
classified. 
Results: In VaI-HeFT, a reduction in HF and CV hospitalization rate with valsartan is 
observed in' all subgroups except those treated with both ACE and BB. The number of 
patients hospitalized also was reduced by valsartan compared to placebo, particularly 
those hospitalized more than once (1: HF 8.7%, CV 7.5%; 2 or more: HF 20.7%, CV 
11.6%). 
Conclusion: The beneficial affects on the overall HF and CV hospitalization rates in Val- 
HeFT confirm the adjudicated first HF hospitalization sndpoint. Reduction of hospitaliza- 
tion rates is most strongly noted in patients with recurrent hospitalizations. 
HF Hospitalizations 
Total Number Per patient-year 
Subgroup Valsartan Placebo Valsartan Placebo p-value 
All 923 1189 0.30 0.36 0.001 
BB=yes 266 298 0.25 0.24 0.686 
BB=no 657 891 0.32 0.43 <0.001 
ACE=yes 872 1072 0,31 0.35 0.011 
ACE=no 51 117 0.18 0,51 0.007 
BB(y)+ACE(y) 254 269 0,27 0,22 0.953 
BB(y)+ACE(n) 12 29 0.11 0,45 0.102 
BB(n)+ACE(y) 618 803 0.33 0.42 0,002 
BB(n)+ACE(n) 39 88 0.22 0.55 0.032 
1134-160 Early Detection of Regional Myocardial Dysfunction by 
Strain Doppler Echocardlogrephy in Patients With 
Primary Amyloidosis 
Jun Kovama, Patricia A. Ray-Sequin, Giulia Russo, Rodney H. Falk, Boston Medical 
Center, Boston, Massachusetts. 
Background: Tissue Doppler imaging (TDI) shows a reduced longitudinal myocardial 
velocity gradient between the base and mid-ventricle in amyloidosis with heart failure 
(CHF). We sought to determine the precise site of the regional contractile abnormality 
using strain rate imaging (SRI). 
Methods: 88 biopsy-proven patients with AL amyloidosis underwent TDI and SRI. 54 had 
heart involvement, of whom 26 had CHE 28 had cardiac involvement but no CHF and 34 
had non-cardiac amyloid (controls). Sample volumes were placed on basal, mid, and api- 
cal ventricle at the septum, lateral, and inferior walls in the apical views. Peak TDI and 
SRI were measured in systole (S) and early (E) diastole. 
Results: Using TDI, differences in systolic function were only apparent between the CHF 
and the other 2 groups, but TDI could not distinguish the controls from "no-CHF". In con- 
treat, peak SRI-S distinguished "no-CHF" from controls. The difference was most appar- 
ent at the mid-ventricle (table), whereas basal peak SRI-S did not differ between "no- 
CHF" and controls. Similarly, peak SRI-E in the "no-CHF" showed a significantly lower 
value than in the controls at the mid-ventdcle but not the base, whereas TDI-E did not 
show any difference between the 'no-CRF" and controls. 
Conclusion: In cardiac amyloid, systolic and diastolic myocardial dysfunction show 
regional differences. Dysfunction is seen prominently and earliest in the mid-ventricular 
walls. The abnormalities, while poorly detected by TDI, can be demonstrated by SRI. 
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SRI and TDI at mid-ventricle in systole 
peak systolic value Control (n=34) No-CHF (n=28) CHF (n=26) 
IVS SRI -1.8±0.5 -1.2±0.7 1" -0.7±0.5"i" ** 
LAT SRI -t .7±0.6 -1.4±0.5 * -0,8±0.51. ** 
INF SRI -1.6±0.7 -1.2±0.6 * -0.8±0.6 1. ** 
IVS TDI 3.7¢1.1 3.9±1.4 2.5±1.2 1" 1.1. 
LAT TDI 3.4±1.8 2.5±1.2 * 2.4±1.3 * 
INF TDI 4.0±1.2 3.7±1.3 2.4±1.3 1. 1.1. 
*:P<0.05 vs.Control 1": P<0.001 vs. Control **:P<0.05 vs. No-CHF 1"'i-:P<0.001 vs.No- 
CHF 
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1135-141 Long-Term Beneficial Effects of Neonatal 
Cardiomyocytes on Left Ventricular Ejection Fraction, 
Regional Wall Motion, and Scar Thickness After 
Transplantation Into Infarcted Rat Hearts 
Jochen Muller-Ehmsen. Kirk L. Peterson, Larry Kedes, Peter Whittaker, Joan S. Dow, 
Robert A. Kloner, Heart Institute Good Samaritan Hospital, Los Angeles, Cafifornia. 
The long-term effects of cardiac cell transplantation on myocardial dysfunction are 
unknown. We tested, therefore, the impact of neonatal cardiomyocytes on cardiac con- 
tractility, left ventricular (LV) volumes and LV geometry 6 months after transplantation into 
infarcted hearts. Cardiomyocytes from male neonatal Fischer 344 rats (1-2 d, 3-5 x 106/ 
50 IJI) or medium were injected into the infarcts of adult syngeneic female animals 1 week 
after left coronary artery ligation. LV angiography 6 months after cell transplantation 
revealed a greater ejection fraction in treated animals than in control (0.36±0.03 vs. 
0.25±0.02, both n=9, P<0.01). 55.1±7.3% of the myocardial infarct zone was dyskinetic 
in control rats vs. 29.5:~8.3% in cell treated rats (P=0.035). Average chordat shortening 
within the myocardial infarct zone was negative in controls but positive in treated rats 
(P=0.02). LV hemodynamics (n=9 each) showed similar enddiastolic pressures, maximal 
systolic pressures and maximal rates of rise and fall of ventricular pressure (+dP/dt, -dP/ 
dt). Post mortem, hearts were fixed in distension (10 mmHg intracavity pressure), and LV 
geometry data were obtained. LV volumes and infarct sizes were similar in the treated 
group as in control (0.42±0.02 vs. 0.45±0.03 ml and 31.5¢1.7 vs. 34.2+2.8%), but scar 
thickness was greater in treated animals (909±97 1~m vs. 619±41 I~m, P<0.02). 
Previously, we have shown that more than half of neonatal cardiomyocytes urvive for at 
least 6 months after transplantation into infarcted hearts. Transplanted neonatal cells 
reduced regional dyskinesis and had a small beneficial effect on systolic contraction. For 
the first time, it has been shown that cell transplantation therapy improves long-term in 
vivo global and regional left ventricular function after myocardial infarction. 
1135-142 Ident i f i cat ion  o f  Genes Involved in Acute Rejection 
Following Heart Transplantation in a Murine Model: Use 
of cDNA Arrays 
Ana L. S. Roussoulieres, Olivier Raisky, Lara Chalabreysse, George Dureau, Pascale 
Boissonnat, Jean-Francois Obedia, Francoise Thivolet-Bejui, John L. McGregor. Hopital 
Cardiologique Louis Pradel, Lyon, France, INSERM U331, Lyon, France. 
Objectives: To identify gene clusters that are over- or under-expressed, in acute rejection 
in a murine model of heterotopic heart transplantation. 
Methods: Hearts from Balb/c mice were transplanted heterotopically in the abdomen of 
Balb/c (isografts) and C57BIJ6 mice (ailografts). The mice did not receive immunosup- 
pressive treatment. The rejection in the allograft group, was confirmed by the presence of 
lynphocytic infiltrate and myocyte damage using light microscopy. Total RNA was 
extracted from mice hearts that were not transplanted (group NT), from isografts (group I) 
and from allografts (group A). The isolated RNA, DNase treated, was amplified and 
labelled with P32 in a reverse transcriptase reaction. Each probe was hybridised to cDNA 
arrays containing 1176 genes (Atlas Mouse 1.2 Array-Clontech, CA). The relative 
expression levels of a given cDNA from two different RNA sources could be compared 
using the software Atlas 1.01-Clontach. 
Results: Transcription profile was obtained for the three subgroups (NT, I, A). In analys- 
ing these experiments we find that 11 genes were found upregulated in the acute rejec- 
tion group (A) when compared to the control group (NT). Upregulatad genes, include 
Macrophage Inflammatory Protein 1 beta (MIP-1 beta: 272'fold), Interferon Inducible Pro- 
tein 1 (46 fold), Interferon Regulatory Factor 1 (21 fold), Signal Transducer and Activator 
of Transcription 1 (14 fold). Twelve genes were found downregulated in the acute rejec- 
tion group as the VE-Cadherin (17 fold). Validation by immunohistochemistry confirms 
the overexpression of MIP-1 beta and underexpression of VE-Cadherin in the acute 
rejection group (group A). 
Conclusion: Our results suggest that the production of MIP-1 beta and the suppression of 
the VE-Cadherin production by the endothelial cells may participate in the early phase of 
an acute rejection, indeed, these proteins may be implicated in the regulation of leuko- 
cyte recruitment and migration into the myocardial tissue, cDNA arrays offers a powerful 
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tool to study transcription profile patterns in acute allograff rejection. Such transcription 
profiles may be of great help in identifiJing new diagnostic and/or therapeutic tools in 
acute rejection. 
1135-143 Mesenchymal Stem Cell Therapy Prevents Deterioration 
of  Left  Ventricular Function in a Porcine Myocardial 
Infarction Model 
Mohammed S. Qaw~lm, Kaname Takizawa, Malka Frantzen, Robb MecLellan, Michael 
Lill, Michael C. Fishbein, Takashi Miyamoto, Raj Makkar, Cedars-Sinai Medical Center, 
Los Angeles, California. 
Background: Bone marrow derived mesenchymal stem cells (MSC) are capable of dif- 
ferentiating into cardiomyocytes in-vitro. In rodent models of myocardial infarction 
implantation of MSC improves ventricular function. We aimed to test the hypothesis that 
a similar beneficial affect of MSC therapy may be observed in a large animal model of 
myocardial infarction. 
Methods: To test this hypothesis, we developed a porcine model of LV dysfunction. An 
apical myocardial infarction was induced by coil embolization of the distal LAD. Biplane 
ventriculography was used to measure ejection fraction (EF) pre and post-ML At one 
month post-MI, animals underwent thoracotomy and epicardial injection into the apical 
scar (27 g needle, 3 ml final volume) of either 150 million MSC (cell group) or growth 
media alone (placebo group). Prior to injection, MSC were labeled in-vitro with BrdU. At 3 
months post-MI (2 months post.injection), animals were sacrificed and the heart removed 
for histology. 
Results: Ejection fraction decreased in both groups 1 month after MI (before cell trans- 
plantation), by 8% (placebo group, n=8) and 5% (cell group, not significantly different, 
n=10). At 3 months post-M1 (2 months after cell transplantation) ejection fraction had 
decreased from the pre-MI baseline by 17% (n=8) in the placebo group versus 5% (n=5) 
in the cell therapy group (p<O.05). Histology revealed BrdU labeled MSC in infarct tissue 
2 months post-cell transplantation. 
Conclusions: Epicardial injection of mesenchymal ste~ cells into scar tissue prevents 
further adverse deterioration in LV function in a chronic MI animal model. Mesechymal 
stem cells are capable of surviving in infarct tissue up to 2 months following transplanta- 
tion, 
1135-144 The Growing Threat of Malignancies Under Various 
Heart Transplant Immunosuppreasive Regimens From s 
Single Institution 
Bijal Patel, Maria L, Espejo, Eric Sue, Sheryllene Go, Jon A. Kobashigawa. University of 
California, Los Angeles, Los Angeles, California. 
Background: MaLignancy in heart transplant recipients has been reported to occur in 
approximately 5% of patients. This incidence may be an underestimation as average 
time on immunosuppressive medication and average age of the heart transplant recipient 
increases. It is also not clear whether different immunosuppressive regimens lead to 
more or less development of malignancies. Method: We reviewed 705 adult heart trans- 
plant patients with five-year followup from our institution (standardized followup proto- 
cols) to assess the incidence of malignancies and the impact of various 
immunosuppressive regimens. Average recipient age was 53.6 years and average fol- 
Iowup tome was 5.1 years. Patients were grouped into the following immunosupprassive 
regimens (at the time of initial hospital discharge): Group 1 (n=458), cyclosporine (CSA)/ 
azathioprine (AZA); Group 2 (n=33), tacrolimus (TAC)/AZA; Group 3 (n=137), CSN 
myphenolate mofetil (MMF); Group 4 (n=30), TAC/MMF. Results: For five-year follow-up, 
malignancies were observed in 141 of 705 (20.0%) heart transplant recipients. This 
included; 23.1% Group 1, 18.1% Group 2, 19.0% Group 3, and 6.7% Group 4 patients. 
The more common malignancies were similar in incidence in all groups and are seen in 
the table. Conclusion: The incidence of malignancies following head transplantation is 
higher than reported despite immunosuppressive regimens. Further study and preventive 
measures are needed to reduce the incidence of this significant and growing} problem. 
Group N % Skin % Lymphoma % Lung % Colon % Prostate % Breast 
CSA/AZA 458 10.5 2.6 2.0 0.9 1.7 1.3 
TAC/AZA 33 15.1 0 3.0 0 0 0 
CSNMMF 137 8.8 1.5 1.5 0.2 2.2 1.5 
TAC/MMF 30 3.3 3.3 0 0 0 0 
